[Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate].
Case1 was a 52-year-old man who had recurrence of postoperative intra-abdominal disseminations from gastrointestinal stromal tumor (GIST) of the jejunum. Case2 was a 66-year-old man who had GIST of the jejunum with multiple liver metastases. Two cases presented hemoperitoneum caused by administration of imatinib mesylate, and we conducted emergent surgery. In spite of surgically non-curative cases, it is suggested that the surgical management for GIST of high grade group with peritoneal exposure should be followed by the administration of imatinib mesylate.
Yokoyama
Akira
A
Department of Gastroenterology, Iwaki Kyoritsu General Hospital.
Dairaku
Naohiro
N
Kusano
Masao
M
Koshita
Shinsuke
S
Shimada
Norihiro
N
Yamagiwa
Tetsuya
T
Kojima
Yasuhiro
Y
Ojima
Toshiaki
T
Ikeya
Shinichi
S
Nakayama
Haruo
H
Sugai
Yoshiki
Y
Hiwatashi
Nobuo
N
Asano
Shigeyuki
S
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001549:Benzamides; D003131:Combined Modality Therapy; D013505:Digestive System Surgical Procedures; D004630:Emergencies; D017809:Fatal Outcome; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000601:surgery*; D006465:Hemoperitoneum / Q000139:chemically induced*; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate